mr QUARDRICOS DRISKELL

1. Fiscal Year 2017 Labor, Health and Human Services, Education and Related Agencies Appropriations Act to help patients by urging Congress to implement a public health agenda through the Centers for Disease Control and Prevention by requesting $1.5 million to support a psoriatic disease initiative to better understand linkages between psoriatic disease and other life-threatening health conditions and to develop effective public health strategies to better equip patients to manage their health. 2. S. 1014, the Personal Care Products Safety Act, the bill strengthens FDA authority to regulate personal care products, addresses questions about the safety of certain ingredients (use by many psoriatic disease patients), creates guidance for manufacturers, and would set a national standard for cosmetics oversight. 3. S. 2113 Crowdsourcing and Citizen Science Act of 2015, the bill would encourage and increase the use of crowdsourcing and citizen science within the federal government. 4. Patients Access to Treatments Act (H.R. 1600), the bill limits cost sharing and out-of-pocket expenses for specialty tier drugs. 5. S.1488/ H.R. 2624 The Part D Beneficiary Appeals Fairness Act, the bill would allow Medicare Part D beneficiaries to request lower co-pays for high-cost specialty drugs used to treat chronic illnesses.

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other cost sharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Worked with CDC's Chronic Disease Prevention and Health Promotion on initiative that will develop public health self-management interventions for persons with psoriatic disease and advance knowledge of the links between psoriatic disease and other chronic conditions 4. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other cost sharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Worked with CDC's Chronic Disease Prevention and Health Promotion on initiative that will develop public health self-management interventions for persons with psoriatic disease and advance knowledge of the links between psoriatic disease and other chronic conditions 4. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure 5.21st Century Cures Act - biomedical research bill 6. Crowdsourcing and Citizen Science Act of 2015 American Innovation Act

1. Fiscal Year 2017 Labor, Health and Human Services, Education and Related Agencies Appropriations Act to help patients by urging Congress to implement a public health agenda through the Centers for Disease Control and Prevention by requesting $1.5 million to support a psoriatic disease initiative to better understand linkages between psoriatic disease and other life-threatening health conditions and to develop effective public health strategies to better equip patients to manage their health. 2. S. 1014, the Personal Care Products Safety Act, the bill strengthens FDA authority to regulate personal care products, addresses questions about the safety of certain ingredients (use by many psoriatic disease patients), creates guidance for manufacturers, and would set a national standard for cosmetics oversight. 3. S. 2113 Crowdsourcing and Citizen Science Act of 2015, the bill would encourage and increase the use of crowdsourcing and citizen science within the federal government. 4. Patients Access to Treatments Act (H.R. 1600), the bill limits cost sharing and out-of-pocket expenses for specialty tier drugs. 5. S.1488/ H.R. 2624 The Part D Beneficiary Appeals Fairness Act, the bill would allow Medicare Part D beneficiaries to request lower co-pays for high-cost specialty drugs used to treat chronic illnesses. 6. 21st Century Cures Act, set appropriated funds for biomedical research at NIH and reforms to the FDA to develop and implement a strategic plan for biomedical research

1. Fiscal Year 2017 Labor, Health and Human Services, Education and Related Agencies Appropriations Act to help patients by urging Congress to implement a public health agenda through the Centers for Disease Control and Prevention by requesting $1.5 million to support a psoriatic disease initiative to better understand linkages between psoriatic disease and other life-threatening health conditions and to develop effective public health strategies to better equip patients to manage their health. 2. S. 1014, the Personal Care Products Safety Act, the bill strengthens FDA authority to regulate personal care products, addresses questions about the safety of certain ingredients (use by many psoriatic disease patients), creates guidance for manufacturers, and would set a national standard for cosmetics oversight. 3. S. 2113 Crowdsourcing and Citizen Science Act of 2015, the bill would encourage and increase the use of crowdsourcing and citizen science within the federal government. 4. Patients Access to Treatments Act (H.R. 1600), the bill limits cost sharing and out-of-pocket expenses for specialty tier drugs. 5. S.1488/ H.R. 2624 The Part D Beneficiary Appeals Fairness Act, the bill would allow Medicare Part D beneficiaries to request lower co-pays for high-cost specialty drugs used to treat chronic illnesses.

1. Fiscal Year 2017 Labor, Health and Human Services, Education and Related Agencies Appropriations Act to help patients by urging Congress to implement a public health agenda through the Centers for Disease Control and Prevention by requesting $1.5 million to support a psoriatic disease initiative to better understand linkages between psoriatic disease and other life-threatening health conditions and to develop effective public health strategies to better equip patients to manage their health. 2. S. 1014, the Personal Care Products Safety Act, the bill strengthens FDA authority to regulate personal care products, addresses questions about the safety of certain ingredients (use by many psoriatic disease patients), creates guidance for manufacturers, and would set a national standard for cosmetics oversight. 3. S. 2113 Crowdsourcing and Citizen Science Act of 2015, the bill would encourage and increase the use of crowdsourcing and citizen science within the federal government. 4. Patients Access to Treatments Act (H.R. 1600), the bill limits cost sharing and out-of-pocket expenses for specialty tier drugs. 5. S.1488/ H.R. 2624 The Part D Beneficiary Appeals Fairness Act, the bill would allow Medicare Part D beneficiaries to request lower co-pays for high-cost specialty drugs used to treat chronic illnesses.

1. Fiscal Year 2017 Labor, Health and Human Services, Education and Related Agencies Appropriations Act to help patients by urging Congress to implement a public health agenda through the Centers for Disease Control and Prevention by requesting $1.5 million to support a psoriatic disease initiative to better understand linkages between psoriatic disease and other life-threatening health conditions and to develop effective public health strategies to better equip patients to manage their health. 2. S. 1014, the Personal Care Products Safety Act, the bill strengthens FDA authority to regulate personal care products, addresses questions about the safety of certain ingredients (use by many psoriatic disease patients), creates guidance for manufacturers, and would set a national standard for cosmetics oversight. 3. S. 2113 Crowdsourcing and Citizen Science Act of 2015, the bill would encourage and increase the use of crowdsourcing and citizen science within the federal government. 4. Patients Access to Treatments Act (H.R. 1600), the bill limits cost sharing and out-of-pocket expenses for specialty tier drugs. 5. S.1488/ H.R. 2624 The Part D Beneficiary Appeals Fairness Act, the bill would allow Medicare Part D beneficiaries to request lower co-pays for high-cost specialty drugs used to treat chronic illnesses. 6. 21st Century Cures Act, set appropriated funds for biomedical research at NIH and reforms to the FDA to develop and implement a strategic plan for biomedical research

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other cost sharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Worked with CDC's Chronic Disease Prevention and Health Promotion on initiative that will develop public health self-management interventions for persons with psoriatic disease and advance knowledge of the links between psoriatic disease and other chronic conditions 4. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure 5.21st Century Cures Act - biomedical research bill 6. Crowdsourcing and Citizen Science Act of 2015 American Innovation Act

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other cost sharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Worked with CDC's Chronic Disease Prevention and Health Promotion on initiative that will develop public health self-management interventions for persons with psoriatic disease and advance knowledge of the links between psoriatic disease and other chronic conditions 4. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Fiscal Year 2017 Labor, Health and Human Services, Education and Related Agencies Appropriations Act to help patients by urging Congress to implement a public health agenda through the Centers for Disease Control and Prevention by requesting $1.5 million to support a psoriatic disease initiative to better understand linkages between psoriatic disease and other life-threatening health conditions and to develop effective public health strategies to better equip patients to manage their health. 2. S. 1014, the Personal Care Products Safety Act, the bill strengthens FDA authority to regulate personal care products, addresses questions about the safety of certain ingredients (use by many psoriatic disease patients), creates guidance for manufacturers, and would set a national standard for cosmetics oversight. 3. S. 2113 Crowdsourcing and Citizen Science Act of 2015, the bill would encourage and increase the use of crowdsourcing and citizen science within the federal government. 4. Patients Access to Treatments Act (H.R. 1600), the bill limits cost sharing and out-of-pocket expenses for specialty tier drugs. 5. S.1488/ H.R. 2624 The Part D Beneficiary Appeals Fairness Act, the bill would allow Medicare Part D beneficiaries to request lower co-pays for high-cost specialty drugs used to treat chronic illnesses.

1. Fiscal Year 2017 Labor, Health and Human Services, Education and Related Agencies Appropriations Act to help patients by urging Congress to implement a public health agenda through the Centers for Disease Control and Prevention by requesting $1.5 million to support a psoriatic disease initiative to better understand linkages between psoriatic disease and other life-threatening health conditions and to develop effective public health strategies to better equip patients to manage their health. 2. S. 1014, the Personal Care Products Safety Act, the bill strengthens FDA authority to regulate personal care products, addresses questions about the safety of certain ingredients (use by many psoriatic disease patients), creates guidance for manufacturers, and would set a national standard for cosmetics oversight. 3. S. 2113 Crowdsourcing and Citizen Science Act of 2015, the bill would encourage and increase the use of crowdsourcing and citizen science within the federal government. 4. Patients Access to Treatments Act (H.R. 1600), the bill limits cost sharing and out-of-pocket expenses for specialty tier drugs. 5. S.1488/ H.R. 2624 The Part D Beneficiary Appeals Fairness Act, the bill would allow Medicare Part D beneficiaries to request lower co-pays for high-cost specialty drugs used to treat chronic illnesses. 6. 21st Century Cures Act, set appropriated funds for biomedical research at NIH and reforms to the FDA to develop and implement a strategic plan for biomedical research

1. Fiscal Year 2017 Labor, Health and Human Services, Education and Related Agencies Appropriations Act to help patients by urging Congress to implement a public health agenda through the Centers for Disease Control and Prevention by requesting $1.5 million to support a psoriatic disease initiative to better understand linkages between psoriatic disease and other life-threatening health conditions and to develop effective public health strategies to better equip patients to manage their health. 2. S. 1014, the Personal Care Products Safety Act, the bill strengthens FDA authority to regulate personal care products, addresses questions about the safety of certain ingredients (use by many psoriatic disease patients), creates guidance for manufacturers, and would set a national standard for cosmetics oversight. 3. S. 2113 Crowdsourcing and Citizen Science Act of 2015, the bill would encourage and increase the use of crowdsourcing and citizen science within the federal government. 4. Patients Access to Treatments Act (H.R. 1600), the bill limits cost sharing and out-of-pocket expenses for specialty tier drugs. 5. S.1488/ H.R. 2624 The Part D Beneficiary Appeals Fairness Act, the bill would allow Medicare Part D beneficiaries to request lower co-pays for high-cost specialty drugs used to treat chronic illnesses.

1. Fiscal Year 2017 Labor, Health and Human Services, Education and Related Agencies Appropriations Act to help patients by urging Congress to implement a public health agenda through the Centers for Disease Control and Prevention by requesting $1.5 million to support a psoriatic disease initiative to better understand linkages between psoriatic disease and other life-threatening health conditions and to develop effective public health strategies to better equip patients to manage their health. 2. S. 1014, the Personal Care Products Safety Act, the bill strengthens FDA authority to regulate personal care products, addresses questions about the safety of certain ingredients (use by many psoriatic disease patients), creates guidance for manufacturers, and would set a national standard for cosmetics oversight. 3. S. 2113 Crowdsourcing and Citizen Science Act of 2015, the bill would encourage and increase the use of crowdsourcing and citizen science within the federal government. 4. Patients Access to Treatments Act (H.R. 1600), the bill limits cost sharing and out-of-pocket expenses for specialty tier drugs. 5. S.1488/ H.R. 2624 The Part D Beneficiary Appeals Fairness Act, the bill would allow Medicare Part D beneficiaries to request lower co-pays for high-cost specialty drugs used to treat chronic illnesses. 6. 21st Century Cures Act, set appropriated funds for biomedical research at NIH and reforms to the FDA to develop and implement a strategic plan for biomedical research

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda.

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

-Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH.

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda.

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-calledspecialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. -Ensure that Medicare Advantage networks are providing patients with adequate and timely access to providers with appropriate training and specialty expertise by copsonsoring HR.4998/S.2552

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure.

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure.

-Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following bill: efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R.460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -Engagement with the Food and Drug Administration (FDA) on the patient focused drug development initiative in the form of submitted comments. Additional engagement with FDA dermatology staff on the latest in psoriasis research, the NPFs current focus and drug therapy development views from the patient community.

Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-calledspecialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. -Ensure that Medicare Advantage networks are providing patients with adequate and timely access to providers with appropriate training and specialty expertise by copsonsoring HR.4998/S.2552

Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-calledspecialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. -Ensure that Medicare Advantage networks are providing patients with adequate and timely access to providers with appropriate training and specialty expertise by copsonsoring HR.4998/S.2552

Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-calledspecialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. -Ensure that Medicare Advantage networks are providing patients with adequate and timely access to providers with appropriate training and specialty expertise by copsonsoring HR.4998/S.2552

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure.

Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-calledspecialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. -Ensure that Medicare Advantage networks are providing patients with adequate and timely access to providers with appropriate training and specialty expertise by copsonsoring HR.4998/S.2552